Watchlist

Watchlist
AnaptysBio, Inc. (ANAB)
Key events next week - healthcare
Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more …
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ…
Midday Gainers / Losers (4/5/2018)
Gainers: LFIN +81% . NETE +26% . NVCN +26% . I +18% . VERI +18% . VTNR +12% . SNOA +14% . FTFT +15% . PLSE +14% . LEDS +13% . More news on: LongFin Corp, Net Element International, Inc., Neovasc Inc., Stocks on the move, , Read more …
Premarket analyst action - healthcare
Dexcom (NASDAQ: DXCM ) initiated with a Sell rating and $57 (24% downside risk) price target at Goldman Sachs. Initiated with Neutral rating at Guggenheim. Shares down 5% premarket. More news on: DexCom, Inc., NuVasive, Inc., Nevro, Healthcare stocks news, Stocks on the move, ,…
Aimmune Still Leads In The Peanut Allergy Race
One of the main recent stumbling blocks to upward movement in Aimmunes (AIMT) stock has been concern coming from a perceived existential threat to Aimmunes prospects from AnaptysBios (ANAB) monoclonal antibody approach to treating peanut allergy. Since the release of Ai…
Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data
Analysis focus: Esperion Esperion Therapeutics (ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study ( 1002-039 ) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein…
AnaptysBio (ANAB) ANB020 Phase 2a Peanut Allergy Data - Slideshow
The following slide deck was published by AnaptysBio in conjunction with this Read more …
U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018
The U.S. equity indexes rebounded today from key 200-day moving average support level after trade negotiations between the U.S. and China were reported. The buying accelerated later in the day indicating institutional interest (advancers: decliners= 68%: 23%). While it is unclear if we have se…
After Hours Gainers / Losers (3/26/2018)
Top gainers: ANAB +7.5% . RHT +4.9% . BHVN +4.5% . QTNT +2.2% . PTGX +2.1% . More news on: AnaptysBio, Red Hat, Inc., Biohaven Pharmaceutical Holding Company Ltd., Stocks on the move, , Read more …
AnaptysBio, Inc. (ANAB)